We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Recommends Trial Designs for Unresponsive Non-Muscle Invasive Bladder Cancer
FDA Recommends Trial Designs for Unresponsive Non-Muscle Invasive Bladder Cancer
Clinical trial design in non-muscle invasive bladder cancer should depend on whether patients have active disease at the time of enrollment, the FDA said, in a draft guidance that focuses on developing drugs and biologics for disease that has not responded to standard bacillus Calmette-Guerin immunotherapy.